undefinedSouth China Morning Post
Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.
We are aware of reports of the Wuhan Institute for Virology’s patent application,” Sonia Choi, Gilead’s vice president of public affairs, said in an email reply to the South China Morning Post.
“Our focus at this time is on rapidly determining the potential for remdesivir as a treatment for [the novel coronavirus] and accelerating manufacturing in anticipation of potential future supply needs
Asked if Gilead will contest the patent application filed by the Chinese researchers, she said China’s “application has been filed more than three years after Gilead’s filing and will be considered in view of what is already known about the compound and pending patent applications.
One question is whether the specific combination of drugs or that specific medical use of the drug is novel, that is, the researchers who make a discovery have filed their patent application before it becomes known to the public,” Cobden said.
Even if the Institute of Virology is granted the patent for the use of the drug on the novel coronavirus, it would not be able to get around any patents Gilead might have filed or obtained for the drug remdesivir
“But a patent cannot stop doctors from prescribing the drug to treat a patient.”